2024/12/3(二)第1366次例會(寶眷週)
時    間：晚上18:30
地    點：晶華酒店
主講人：洪懿珮(向榮生醫科技股份有限公司總經理)
講    題：再生醫學快樂新膝旺
※歡迎社友& 寶尊眷報名出席，非常感謝

全球人口老化，

Good News...壽命延長，

but...生命及生活品質？

向榮生技聚焦於以幹細胞解決老化問題的醫療需求已十餘年。
本公司幹細胞新藥『ELIXCYTE®』正進行第3期膝骨關節炎收案，針對眾多腎臟疾病患者的慢性腎臟病臨床第1/2期試驗也已完成。
向榮生技希望為全球人口老化所伴隨之退化或不可逆疾病，提供一個嶄新的治療契機，改善老年退化導致不良於行或機能衰退之生命威脅及提高病人的生活品質，享受快樂的樂齡生活。

Global Population Aging
Good News... Longer Lifespan,
but... What About Life and Health Quality?
For over a decade, Unicocell has been dedicated to addressing the medical needs of aging-related issues through stem cell solutions.
Our stem cell drug, ELIXCYTE®, is currently in Phase 3 clinical trials for knee osteoarthritis. Additionally, we have completed Phase 1/2 clinical trials targeting chronic kidney disease, a condition affecting many renal patients.
Unicocell aims to provide innovative treatment opportunities for degenerative or irreversible diseases associated with global aging. Our mission is to address life-threatening conditions caused by aging-related degeneration, enhance patients' quality of life, and help them enjoy a joyful and healthy senior life.